ArticleDiscover oncology2025
Vision transformer network discovers the prognostic value of pancreatic cancer pathology sections via interpretable risk scores.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Maximizing pancreatic carcinoma classification performance using parrot optimized vision transformer.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pathological sections hold rich diagnostic information, yet their prognostic potential is underutilized. This study leverages deep learning to predict outcomes, advancing precision oncology of pathological sections with focus on pancreatic cancer. We analyzed H&E-stained whole section images of 125 cases from public databases as well as 28 real-world patients with pancreatic cancer and precancerous lesions. After image preprocessing, we identified and selected representative patches for subsequent analysis. We develop a modified visual transformer (ViT) model with spatial attention and fine-tuned on ImageNet2012, which was subsequently used to predict the survival times of the corresponding patients and to calculate risk scores. The modified ViT model demonstrated strong predictive accuracy for patient prognosis, with C-indices of 0.79 and 0.82 for Overall Survival (OS) and Disease Free Survival (DFS) in the test set and 0.62 in the validation set. Risk scores correlated well with patient survival, showing clustering between 0.17 and 0.95, aligning with a median survival of 24 months. Higher risk scores were associated with worse clinical prognosis, including shorter survival times and increased tumor recurrence risk, validated across all datasets. The model's AUCs for OS and DFS prediction reached 0.847/0.849 in the training set and 0.813/0.834 in the test set, confirming its high accuracy and potential for clinical application in risk stratification and prognosis prediction. ViT network can discover the prognostic value of pancreatic cancer pathology sections via interpretable risk scores, providing a new insight for prognosis evaluation as well as opens new technology building on existing clinical diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.